Global Healthcare Study on Psoriasis
ConditionPsoriasis (PsO)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14+
SponsorJulia Tatjana Maul
About this trial
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Signed General Consent Form, or equivalent document
Confirmed diagnosis of Psoriasis
Disqualifiers
Inability to provide informed consent.
Datasets with ambiguous or unclear diagnosis.
Trial population
Patient populations across world regions seen for psoriasis.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
9,600 Participants
are grouped into 1 trial groupGroup A: Global Healthcare Study on Psoriasis
Trial outcomes
Primary outcomes
1
Psoriasis Area Severity Index (PASI)
Composite clinician-assessed measure of psoriasis severity based on erythema, scaling, thickness, and affected body surface area; total score ranges from 0 to 72, with higher scores indicating more severe disease.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.Secondary outcomes
1
Dermatology Life Quality Index (DLQI)
Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.2
Nail Psoriasis Severity Index (NAPSI)
Clinician-assessed measure of nail psoriasis severity based on nail matrix and nail bed involvement; scores range from 0-80 for fingernails and 0-80 for toenails; total score ranges from 0-160, with higher scores indicating more severe nail disease.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.3
Numerical Rating Scale (NRS) for disease severity
Patient-reported assessment of psoriasis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable).
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.4
Physician Global Assessment (PGA)
Clinician-assessed global measure of psoriasis severity on a scale from 0 (clear) to 4 (severe).
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Julia Tatjana Maul
Lead sponsor
University of Zurich
Sponsor institution
University of Zurich
Collaborator
University Hospital, Zürich
Collaborator
Source ClinicalTrials.gov